Biblio

9 resultats trouvés
Filtres: Mot-clé is anti-TNF  [Clear All Filters]
D
Wendling D, Goupille P.  2020.  Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis. IMMUNOTHERAPY. 12:857-860.
E
Vallet H., Riviere S., Sanna A., Deroux A., Moulis G., Addimanda O., Salvarani C., Lambert M., Bielefeld P., Seve P. et al..  2015.  Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: Multicenter study of 124 patients. JOURNAL OF AUTOIMMUNITY. 62:67-74.
F
Wendling D, Goupille P.  2020.  From observational studies to personalized treatment in spondylarthritis: focus on IL-17 inhibition. EXPERT OPINION ON BIOLOGICAL THERAPY. 20:837-840.
Wendling D, Goupille P.  2020.  From observational studies to personalized treatment in spondylarthritis: focus on IL-17 inhibition. EXPERT OPINION ON BIOLOGICAL THERAPY. 20:837-840.
I
Launay O, Abitbol V, Krivine A, Ben Slama L, Bourreille A, Dupas JLouis, Hebuterne X, Savoye G, Deplanque D, Bouhnik Y et al..  2015.  Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study. JOURNAL OF CROHNS & COLITIS. 9:1096-1107.
N
Wendling D.  2019.  New targeted therapies in spondyloarthritis: what are the limits? IMMUNOTHERAPY. 11:557-560.
O
Delobeau M, Abdou A, Puzenat E, Deveza E, Biver-Dalle C, van de Laak A, Roche-Kubler B, Vuitton L, Koch S, Wendling D et al..  2016.  Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa. JOURNAL OF DERMATOLOGICAL TREATMENT. 27:251-253.
Thery-Casari C, Jamilloux Y, Bouvry D, Chapelon-Abric C, Marquet A, Bielefeld P, Schleinitz N, Vukusic S, Girszyn N, Fain O et al..  2018.  OUTCOME OF PATIENTS WITH SARCOIDOSIS REFRACTORY TO TNF ANTAGONISTS: A CASE SERIES. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES. 35:371-375.
Reenaers C, Mary J-Y, Nachury M, Bouhnik Y, Laharie D, Allez M, Fumery M, Amiot A, Savoye G, Altwegg R et al..  2018.  Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 16:234+.